The New Antiepileptic Drugs, Scientific Review
JAMA 291:605-614, LaRoche,S.M.&Helmers,S.L., 2004
HIV-Protease Inhibitors
NEJM 338:1281-1292, Flexner,C., 1998
The Use of Parenteral Antiepileptic Drugs & The Role of Fosphenytoin
(Suppl Editor) , Neurol 46:S1-S2896., Wilder,B.J., 1996
Current and Emerging Issues in Wilsons Disease
NEJM 389:922-938, Roberts,E.A. & Schilsky, M.L., 2023
Duchenne Muscular Dystrophy
BMJ 368:L7012, Fox, H.,et al, 2020
Antibody-Mediated Encephalitis
NEJM 378:840-851, Dalmau, J.,et al, 2018
Autoimmune Encephalitides: A Broadening Field of Treatable Conditions
Neurologist 22:1-13, Kalman, B., 2017
Clinicopathologic Conference, Aqueductal Stenosis with Hydrocephalus
NEJM 375:2583-2593, Case 40-2016, 2016
Epilepsy: New Advances
Lancet 385:884-898, Moshe, S.L.,et al, 2015
Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: An IOM Report on Redefining an Illness
JAMA 313:1101-1102, Clayton, E.W., 2015
Therapeutic Devices for Epilepsy
Ann Neurol 71:157-168, Fisher,R.S., 2012
Dilemmas in the Diagnosis of Acute Community-Acquired Bacterial Meningitis
Lancet 380:1684-1692,1623, Brouwer, M.,et al, 2012
Contemporary management and recent advances in paediatric hydrocephalus
BMJ 343:d4191, Kandasamy, J.,et al, 2011
Drug-Resistant Epilepsy
NEJM 365:919-26, Kwan, P.,et al, 2011
Changes in the Incidence and Predictors of Human Immunodeficiency Virus-Associated Dementia in the Era of Highly Active Antiretroviral Therapy
Ann Neurol 63:213-221, Bhaskaran,K.,et al, 2008
Clinical Update:Diagnosis and Treatment of Essential Tremor
Lancet 369:1152-1154, Benito-Leon,J&Louis,E.D., 2007
Postmarketing Modifications in the Safety Labeling of the New Antiepileptics
Neurol 68:1536-1537, Buck,M.L.,et al, 2007
Using Functional Magnetic Resonance Imaging to detect Covert Awareness in the Vegetative State
Arch Neurol 64:1098-1102, Owen,A.M.,et al, 2007
Adult Epilepsy
Lancet 367:1087-1100, Duncan,J.S.,et al, 2006
Patterns of Care for Adults With Newly Diagnosed Malignant Glioma
JAMA 293:557-564,615, Chang,S.M.,et al, 2005
The New Antiepileptic Drugs, Clinical Applications
JAMA 291:615-620, LaRoche,S.M.&Helmers,S.L., 2004
Monotherapy in Epilepsy
Arch Neurol 61:1361-1365, Vazquez,B., 2004
The Shape of Things to Come
Neurol 63:948-950, Hauser,S.L., 2004
Slippery Slopes, Wonder Drugs, and Cosmetic Neurology
Neurol 63:951-952, Dees,R.H., 2004
Cosmetic Neurology: The Controversy Over Enhancing Movement, Mentation, and Mood
Neurol 63:968-974, Chatterjee,A., 2004
Recent Advnaces in the Treatment of Epilepsy
Arch Neurol 60:929-935, Nguyen,D.K. &Spencer,S.S., 2003
Stroke Prevention with the Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin in Patients with Non-Valvular Atrial Fibrillation (SPORTIF III): Randomised Controlled Trial
Lancet 362:1691-1698,1686, Executive Steering Committee on Behalf of the SPOR, 2003
Therapy for the Epilepsies
Arch Neurol 59:732-735, Van Ness,P.C., 2002
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
Evolving Treatment Strategies for Epilepsy
JAMA 287:2917-2920, Diaz-Arrastia,R.,et al, 2002
New Drugs:Which Should Be Included in the Formulary?, Epilepsy:All New Drugs Should Be Included
Arch Neurol 57:272-273,275, Pierre-Louis,S.J.C., 2000
Management of Epilepsy in Adolescents and Adults
Lancet 356:323-329, Brodie,M.J. & French,J.A., 2000
Medical Management of Epilepsy in Adults
Neurol 51:S15-S20, Mattson,R.H., 1999
Recent Advances, Neurology
BMJ 319:362-366, Larner,A.J.&Farmer,S.F., 1999
Clopidogrel for Reduction of Atherosclerotic Events
The Medical Letter 40:59-60, , 1998
Do New Antiepileptic Drugs Justify Their Expense
Arch Neurol 55:1140-1142, Chadwick,D., 1998
New Antiepileptic Drugs
Arch Neurol 55:1181-1183, Bourgeois,B.F.D., 1998
Parenteral Fosphenytoin:Efficacy and Economic Considerations
The Neurologist 4:S30-S34, Ramsay,R.E.&Wilder,B.J., 1998
Assessment of Vagus Nerve Stimulation for Epilepsy
Neurol 49:293-297, Fisher,R.S.,et al, 1997
Surgery for Seizures
NEJM 334:647-652, Engel,J.Jr., 1996
New Antiepileptic Drugs
NEJM 334:1583-1590, Dichter,M.A.&Brodie,M.J., 1996
The 14-3-3 Brain Protein in Cerebrospinal Fluid as a Marker for Transmissible Spongiform Encephalopathies
NEJM 335:924-930, 9631996., Hsich,G.,et al, 1996
New Antiepileptic Drugs:A Systematic Review of Their Efficacy and Tolerability
BMJ 313:1169-1174, 1157, 1158996., Marson,A.G.,et al, 1996
New Antiepileptic Drugs
Neurol 44:787-795, Harden,C.L., 1994
Pharmacogenetics and Drug Metabolism of Newer Antidepressant Agents
J Clin Psychiatry 55:38-45, DeVane,C.L., 1994